Top

Archives of Gynecology and Obstetrics

Published in:

01-11-2020 | General Gynecology

Altered VEGF, Bcl-2 and IDH1 expression in patients with adenomyosis

Authors: Cem Yalaza, Necmiye Canacankatan, İclal Gürses, Hakan Aytan, Bahar Taşdelen

Published in: Archives of Gynecology and Obstetrics | Issue 5/2020

Abstract

Purpose

Adenomyosis is a benign uterine disease resulting from the myometrial invasion of the endometrial gland and stroma. In the current study, angiogenesis, apoptosis and energy metabolism were investigated in adenomyosis.

Methods

A retrospective study was performed using paraffin archival tissues. Three groups were included in the study: Group I and Group II; ectopic and eutopic endometrial tissues of patients with adenomyosis, respectively, and Control Group; endometrial tissue of individuals without adenomyosis. Vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), intercellular adhesion molecule 1 (ICAM-1) and hypoxia-inducible factor 1 alpha (HIF-1A) levels were evaluated as angiogenic markers. Bcl-2, caspase-9 and caspase-3 levels were investigated as apoptotic indicators, and isocitrate dehydrogenase 1 (IDH1), succinate dehydrogenase complex subunit C (SDHC) and fumarate hydratase (FH) levels were also examined as energy metabolism markers. Gene expression levels of all parameters were determined by RT-PCR.

Result

VEGF expression levels were found to be increased in Group I according to the control group and Group II. Bcl-2 expression levels were found to be increased in the Group I compared to the Group II. It was determined that expression levels of IDH1 were decreased in the Group I and Group II compared to the Control Group. There was no significant difference in the other examined parameters. Although we did not find a significant difference in HIF-1A levels between the groups, we found a positive correlation between VEGF and HIF-1A in the Group I.

Conclusion

These results point out that VEGF, HIF-1A, Bcl-2 and IDH1 may be associated with the etiology of adenomyosis.

Abbott JA (2017) Adenomyosis and abnormal uterine bleeding (AUB-A)-pathogenesis, diagnosis, and management. Best Pract Res Clin Obstet Gynaecol 40:68–81CrossRef

Struble J, Reid S, Bedaiwy MA (2016) Adenomyosis: a clinical review of a challenging gynecologic condition. J Minim Invasive Gynecol 23(2):164–185CrossRef

Vannuccini S, Tosti C, Carmona F et al (2017) Pathogenesis of adenomyosis: an update on molecular mechanisms. Reprod Biomed Online 35(5):592–601CrossRef

Koike N, Tsunemi T, Uekuri C et al (2013) Pathogenesis and malignant transformation of adenomyosis. Oncol Rep 29(3):861–867CrossRef

Garavaglia E, Audrey S, Annalisa I et al (2015) Adenomyosis and its impact on women fertility. Iran J Reprod Med 13(6):327–336PubMedPubMedCentral

Ferenczy A (1998) Pathophysiology of adenomyosis. Hum Reprod Update 4:312–322CrossRef

Taran FA, Stewart EA, Brucker S (2013) Adenomyosis: epidemiology, risk factors, clinical phenotype and surgical and interventional alternatives to hysterectomy. Geburtshilfe Frauenheilkd 73(9):924–931CrossRef

Takeda A, Sakai K, Mitsui T, Nakamura H (2007) Laparoscopic management of juvenile cystic adenomyoma of the uterus: report of two cases and review of the literature. J Minim Invasive Gynecol 14:370–374CrossRef

Yuan H, Zhang S (2019) Malignant transformation of adenomyosis: literature review and meta-analysis. Arch Gynecol Obstet 299:47–53CrossRef

10.

Templeman C, Marshall SF, Ursin G et al (2008) Adenomyosis and endometriosis in the California Teachers Study. Fertil Steril 90:415–424CrossRef

11.

Bergeron C, Amant F, Ferenczy A (2006) Pathology and physiopathology of adenomyosis. Best Pract Res Clin Obstet Gynaecol 20:511–521CrossRef

12.

Leyendecker G, Wildt L, Mall G (2009) The pathophysiology of endometriosis and adenomyosis: tissue injury and repair. Arch Gynecol Obstet 280(4):529–538CrossRef

13.

Streuli I, Dubuisson J, Santulli P et al (2014) An update on the pharmacological management of adenomyosis. Expert Opin Pharmacother 15:2347–2360CrossRef

14.

Brosens I, Derwig I, Brosens J et al (2010) The enigmatic uterine junctional zone: the missing link between reproductive disorders and major obstetrical disorders? Hum Reprod 25:569–574CrossRef

15.

Goteri G, Lucarini G, Montik N et al (2009) Expression of vascular endothelial growth factor (VEGF), hypoxia inducible factor-1alpha (HIF-1alpha), and microvessel density in endometrial tissue in women with adenomyosis. Int J Gynecol Pathol 28(2):157–163CrossRef

16.

Kang S, Zhao J, Liu Q et al (2009) Vascular endothelial growth factor gene polymorphisms are associated with the risk of developing adenomyosis. Environ Mol Mutagen 50(5):361–366CrossRef

17.

Jones RK, Searle RF, Bulmer JN (1998) Apoptosis and bcl-2 expression in normal human endometrium, endometriosis and adenomyosis. Hum Reprod 13(12):3496–3502CrossRef

18.

Goumenou A, Panayiotides I, Matalliotakis I et al (2001) Bcl-2 and Bax expression in human endometriotic and adenomyotic tissues. Eur J Obstet Gynecol Reprod Biol 99(2):256–260CrossRef

19.

Kitawaki J (2006) Adenomyosis: the pathophysiology of an oestrogen-dependent disease. Best Pract Res Clin Obstet Gynaecol 20(4):493–502CrossRef

20.

Hever A, Roth RB, Hevezi PA et al (2006) Molecular characterization of human adenomyosis. Mol Hum Reprod 12(12):737–748CrossRef

21.

Herndon CN, Aghajanova L, Balayan S et al (2016) Global transcriptome abnormalities of the eutopic endometrium from women with adenomyosis. Reprod Sci 23(10):1289–1303CrossRef

22.

Han Y, Zhou Y, Zheng S (2002) Study on the expression of vascular endothelial growth factor in patients with adenomyosis of the uterus. Zhonghua Fu Chan Ke Za Zhi 37:539–541PubMed

23.

Orazov MR, Nosenko EN, Radzinsky VE et al (2016) Proangiogenic features in chronic pelvic pain caused by adenomyosis. Gynecol Endocrinol 32(sup2):7–10CrossRef

24.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674CrossRef

25.

Morin A, Letouzé E, Gimenez-Roqueplo AP, Favier J (2014) Oncometabolites-driven tumorigenesis: from genetics to targeted therapy. Int J Cancer 135(10):2237–2248CrossRef

26.

Atkins HM, Bharadwaj MS, O'Brien Cox A et al (2019) Endometrium and endometriosis tissue mitochondrial energy metabolism in a nonhuman primate model. Reprod Biol Endocrinol 17(1):70CrossRef

Title: Altered VEGF, Bcl-2 and IDH1 expression in patients with adenomyosis
Authors: Cem Yalaza
Necmiye Canacankatan
İclal Gürses
Hakan Aytan
Bahar Taşdelen
Publication date: 01-11-2020
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 5/2020
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-020-05742-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Altered VEGF, Bcl-2 and IDH1 expression in patients with adenomyosis

Abstract

Purpose

Methods

Result

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2020

Celiac disease does not influence markers of ovarian reserve in adolescent girls

Controversies in preoperative bowel preparation in gynecologic and gynecologic oncology surgery: a review of the literature

Unilateral cystectomy and serous histology are associated with relapse in borderline ovarian tumor patients with fertility-sparing surgery: a systematic review and meta-analysis

Anti-retroviral therapy failure in HIV-1 infected pregnant women and its associated risk of HIV transmission

A simplified diagnostic work-up for the detection of gestational diabetes mellitus in low resources settings: achievements and challenges

Favorable therapeutic response after anti-Mesothelin antibody–drug conjugate treatment requires high expression of Mesothelin in tumor cells